ReviewFrontiers in tuberculosis2023
Tuberculosis: insights into latency, treatment strategies, and the potential roles of metronidazole.
Review in Frontiers in tuberculosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies challenge the traditional belief that latent tuberculosis is a lifelong condition. Analysis of tuberculosis decline in low endemic areas suggests that latency is diminishing, and a significant proportion of individuals likely clear the infection each year. The risk of developing active tuberculosis diminishes over time, highlighting the importance of early intervention for optimal treatment outcomes. The global estimate of latent tuberculosis infection has been revised to approximately 23% of the global population. Latent bacilli undergo mutation and proliferation, contrary to the previous notion of dormancy. Treatment regimens for tuberculosis, particularly multidrug-resistant strains, have improved with the BPaLM regimen. However, current treatment approaches for drug sensitive tuberculosis do not specifically target dormant bacilli, necessitating the development of better protocols. Metronidazole shows potential in killing non-proliferating
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.